Barclays Stock Rebounds as UK Bank-Tax Fears Collide With Strong Q1 Capital Story

May 13, 2026
Barclays Stock Rebounds as UK Bank-Tax Fears Collide With Strong Q1 Capital Story

London, May 13, 2026, 10:03 BST

  • Barclays rose about 1.3% in London after Tuesday’s bank-sector selloff, a move tied more to calmer UK gilts than to a fresh company catalyst.
  • The bear pressure is still live: political turmoil has revived talk of higher UK bank taxes, while long gilt yields remain high enough to hurt confidence.
  • The bull case rests on Q1 execution: double-digit divisional returns, a £500 million buyback, and management’s confidence in 2026 targets.

Barclays shares were trying to repair some damage Wednesday morning, trading at 420.45p, up 1.34%, after a sharp fall the day before. The move was not a clean “risk-on” rally. It looked more like a partial give-back of Tuesday’s stress, when UK political risk pushed banks lower and gilts into another ugly repricing. Google

That matters because Barclays is now trading like a bank, a gilt proxy, and a UK tax-risk proxy all at once. On Tuesday, long-term UK borrowing costs hit their highest levels in almost three decades, sterling fell, and Barclays, NatWest and Lloyds each dropped more than 3%. JPMorgan also said it now assumes the UK banking surcharge rises to 5% from 3%, a direct earnings headwind for the sector.

The chart moved today because one part of that shock eased. UK bonds stabilized after no clear challenge to Prime Minister Keir Starmer emerged, and broader UK equities opened higher. Banks were part of that rebound, with Barclays, Lloyds, NatWest and Standard Chartered all advancing between 1% and 2% in early trade, according to Trading Economics.

Still, the recovery is thin. The 10-year gilt yield was still above 5%, a level that keeps pressure on the government’s fiscal room, mortgage pricing and business confidence. Kathleen Brooks, research director at XTB, wrote that UK assets were stabilizing as yields fell, but added that the 10-year yield above 5% remains “a big problem” for the economy. Xtb

For Barclays, higher rates cut both ways. They can lift net interest income, meaning the spread between what a bank earns on loans and securities and what it pays for deposits and funding. But high rates also raise default risk, slow deal activity, and invite political scrutiny when bank profits look too strong.

The bull case is still credible. Barclays reported a 13.5% return on tangible equity in Q1, a profitability measure based on hard shareholder capital, and said every division made double-digit returns. CEO C.S. Venkatakrishnan said the bank delivered “another solid quarter” and pointed to broad income growth, a 56% cost-income ratio, a 14.1% CET1 capital ratio — the core capital buffer banks hold against losses — and a new £500 million buyback. Investegate

The bear case is that investors have heard enough good operating news already. Q1 profit before tax rose to £2.8 billion, but Reuters reported that the buyback was smaller than analysts expected and that Barclays booked a £228 million provision tied to MFS, the collapsed lender. That charge pulled attention back to risk controls and private-credit exposure, just as the macro tape turned harsher.

Management’s recent earnings-call tone was constructive, not euphoric. Barclays said stable income streams grew 7%, net interest income excluding the investment bank and head office rose 12%, and the bank had locked in £18.3 billion of gross structural hedge income across 2026–2028. A structural hedge is the portfolio banks use to smooth earnings from deposits over time.

That is why bulls can argue the selloff is more macro than Barclays-specific. The bank has visible income, a buyback, and a capital ratio still inside its target range even after the planned repurchase. JPMorgan’s latest note also kept Barclays and NatWest as longer-term preferred names, citing Barclays at roughly 6 times 2028 estimated earnings and a 10% total yield in 2027.

Bears counter that tax and reserve-remuneration risk can hit exactly the part of the story investors like most: excess capital returns. JPMorgan estimated that a 2-point surcharge rise would cut Barclays’ 2027 EPS by 1.3%, less than Lloyds or NatWest, but a tougher reserve-remuneration change could do far more damage. That is not priced like a normal credit-cycle risk. It is a policy risk.

Prediction markets show why traders are not ready to dismiss the politics. Reuters reported that Polymarket users saw a Starmer departure by the end of June as roughly a coin toss, with year-end departure odds around 80%. On rates, Polymarket’s June Bank of England market showed “no change” at 83% and a 25-basis-point increase at 18%, a split that fits the Barclays debate: rates may stay supportive for income, but the market is no longer treating hikes as impossible. Reuters

The competitive read is mixed. Barclays is more global and investment-bank-heavy than Lloyds and NatWest, so a UK tax hit is smaller in JPMorgan’s estimates; HSBC is even less exposed to the domestic UK profit pool. But Barclays also carries more market-sensitive earnings, and its investment bank, while strong in Q1, still lagged top U.S. rivals in parts of trading and advisory.

So today’s Barclays move is not a reset. It is a bounce inside a new risk frame. The stock has Q1 numbers strong enough to attract buyers on dips, but the next leg depends less on another earnings slide and more on whether UK politics stops feeding the gilt market — and whether bank-tax risk fades or hardens into policy.

Stock Market Today

  • Hantavirus Outbreak Spurs Interest in Vaccine-Linked FTSE 100 Stock Croda
    May 13, 2026, 5:32 AM EDT. The recent hantavirus cases aboard an Argentine cruise ship have not triggered a market-wide panic but are reigniting investor focus on vaccine-related stocks. Moderna's shares climbed nearly 14% amid renewed vaccine development efforts targeting hantavirus. Significantly, Croda International, a FTSE 100 firm that supplies lipids crucial for mRNA vaccines, may see a resurgence after past pandemic-driven demand waned and poorly timed acquisitions weighed on performance. With inventory stabilization and rising vaccine study activity, Croda's shares could present a compelling opportunity. While hantavirus itself is unlikely to prompt a market crash akin to COVID-19's impact, its ripple effects in the pharmaceutical sector warrant investor attention.